An investigational heart failure drug being developed by Novartis cut deaths from heart disease by 20% compared with standard therapy, researchers reported today at the European Society of Cardiology.
Source: www.medpagetoday.com
September 2, 2014 by 2012pharmaceutical
An investigational heart failure drug being developed by Novartis cut deaths from heart disease by 20% compared with standard therapy, researchers reported today at the European Society of Cardiology.
Source: www.medpagetoday.com
Leave a Reply